Biosimilars – commercial best practices in the age of sustainability
What’s the boggle with biologics? If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. Revenues from biologics increased by 70% during 2011–16 to reach $232bn, accounting for roughly 20–22% of total pharmaceutical spending Spending on biologics is also expected to continue to grow even when the impact of biosimilars is considered.
Read more...